Crossmark

Exploring the Use of Molecular Biomarkers for Precision Medicine in Age-Related Macular Degeneration

Crossref DOI link: https://doi.org/10.1007/s40291-018-0332-1

Published Online: 2018-04-26

Published Print: 2018-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lorés-Motta, Laura

de Jong, Eiko K.

den Hollander, Anneke I.
Funding

Funding for this research was provided by:

FP7 Ideas: European Research Council (ERC Grant Agreement n. 310644 (MACULA).)

FP7 Ideas: European Research Council (ERC Grant Agreement n. 737607 (MACULA2).)

FP7 Ideas: European Research Council (317472 (EyeTN).)
License Information

Text and Data Mining valid from 2018-04-26
More Information

Article History

First Online: 26 April 2018

Compliance with Ethical Standards

:

: The research leading to these results has received funding from the European Research Council under the European Union’s Seventh Framework Programme (FP/2007-2013)/ERC Grant Agreement n. 310644 (MACULA). The research leading to these results has received funding from the European Research Council under the European Union’s Horizon 2020 Research and Innovation Programme/ERC Grant Agreement n. 737607 (MACULA2). This project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under Grant agreement no. 317472 (EyeTN).

: The authors LLM and EKdJ declare no conflicts of interest. AIdH declares the following conflicts of interest: consultancy for Ionis Pharmaceuticals, Inc.